Niagen Bioscience Unveils Niagen Plus Telehealth Platform with New At-Home Injection Kit Offering
Niagen Bioscience (NASDAQ: NAGE), widely recognized for its leadership in NAD+ (nicotinamide adenine dinucleotide) research and its focus on advancing the science of healthy aging, has announced the launch of a new clinician-directed telehealth platform under its Niagen™ Plus program. This initiative represents a significant expansion of the company’s access model, enabling eligible patients across the United States to obtain prescription-only, pharmaceutical-grade Niagen from the comfort of their homes.
At the center of this launch is the introduction of the Niagen® At-Home Injection Kit, a first-of-its-kind offering designed to facilitate subcutaneous administration of nicotinamide riboside chloride (NRCl) outside of traditional clinical settings. By integrating telehealth consultations with direct-to-patient delivery, the company is seeking to remove barriers associated with in-person physician visits and pharmacy pickups, thereby expanding access to its NAD+ support therapy while maintaining clinical oversight.
According to Rob Fried, Chief Executive Officer of Niagen Bioscience, the new platform is built around a combination of scientific rigor, patient convenience, and structured medical supervision. He emphasized that the initiative is not merely a shift toward direct-to-consumer distribution, but rather a carefully designed clinician-guided model that ensures patients are evaluated appropriately before gaining access to treatment. The approach reflects the company’s broader commitment to maintaining high standards of quality and evidence-based practice as it scales its offerings.
The telehealth program is structured to guide patients through a comprehensive digital intake process, followed by a consultation with a licensed healthcare provider. During this consultation, clinicians assess patient eligibility based on medical history, health goals, and other relevant factors. Only those who meet the necessary criteria are prescribed the Niagen At-Home Injection Kit, ensuring that access remains controlled and medically appropriate.
Once prescribed, the kit is prepared and dispensed by a licensed 503A compounding pharmacy operating under stringent regulatory and quality standards. The completed package is then shipped directly to the patient’s residence, allowing for seamless initiation of therapy without the need for additional clinic or pharmacy visits. This end-to-end model reflects a growing trend in healthcare toward decentralized, patient-centric delivery systems, particularly in areas such as longevity and preventive medicine.
The Niagen At-Home Injection Kit itself has been carefully designed to support safe and effective administration. It includes a sterile 500 mg vial of Niagen powder, bacteriostatic water for reconstitution, injection syringes, and a separate mixing syringe and needle for preparation. Additional components such as alcohol prep pads are included to support aseptic technique, and patients are provided with detailed, step-by-step instructions accessible via a QR code. This digital guidance ensures that patients can follow proper procedures, even in a home setting.
The therapy is administered subcutaneously, a method chosen for its balance of ease of use and effective delivery. Unlike oral supplementation, which must pass through the digestive system, subcutaneous injection allows Niagen to bypass gut metabolism and enter systemic circulation more directly. Preclinical models have suggested that this route of administration may enhance tissue availability of NAD+ precursors, potentially amplifying their biological effects.
Dosing protocols for the therapy are determined by the prescribing clinician, typically involving 50 mg or 100 mg regimens depending on individual patient needs. The compounded product is manufactured in accordance with current Good Manufacturing Practice (cGMP) standards, ensuring consistency, purity, and quality across batches. These safeguards are particularly important given the increasing interest in NAD+ therapies and the need to differentiate pharmaceutical-grade products from lower-quality alternatives.
The launch of this platform comes at a time of rapid growth in both the injectable therapeutics market and the broader longevity sector. Industry estimates indicate that the U.S. injectable market reached a valuation of over $220 billion in 2025, with projections suggesting steady expansion over the coming decade. Similarly, the longevity market is expected to more than double in size by 2035, driven by rising consumer interest in preventive health, aging-related interventions, and personalized medicine.
Within this context, Niagen Bioscience’s telehealth initiative positions the company to capitalize on these trends while maintaining a focus on clinical integrity. By combining digital health technologies with pharmaceutical-grade products, the company is attempting to bridge the gap between consumer wellness and regulated medical treatment.
Chris Meletis, former Dean and Chief Medical Officer of the National College of Natural Medicine and an advisor to Niagen Bioscience, highlighted the importance of this distinction. He noted that the program is not a casual retail offering, but rather a structured medical pathway that emphasizes patient evaluation and appropriate prescribing. This clinician-directed approach helps ensure that patients receive therapies that are suited to their individual health profiles, rather than engaging in unsupervised self-treatment.
Clinical data supporting the safety of the Niagen At-Home Injection Kit further reinforces its positioning as a medically credible option. In a clinical safety trial, the therapy was generally well tolerated, with no significant adverse effects reported at the tested dose levels of 50 mg/mL and 100 mg/mL. These findings provide an important foundation for broader adoption, particularly as patients and providers seek reassurance regarding the safety of newer delivery formats.
Beyond safety, the potential benefits of NAD+ augmentation continue to be an area of active scientific investigation. NAD+ is a critical coenzyme involved in cellular energy production, DNA repair, and metabolic regulation. Levels of NAD+ naturally decline with age, and this decline has been associated with various aspects of aging and age-related disease. By providing a precursor such as nicotinamide riboside, therapies like Niagen aim to support the body’s ability to replenish NAD+ levels and maintain cellular function.
While research in this area is ongoing, the growing body of evidence has contributed to increased interest among both clinicians and patients. Niagen Bioscience’s approach—combining pharmaceutical-grade formulation, clinician oversight, and convenient delivery—reflects an effort to translate this scientific interest into a practical and scalable healthcare solution.
The introduction of the Niagen Plus telehealth platform also marks a strategic shift for the company, representing its first direct-to-client access model. Historically, access to such therapies has been limited to clinical settings, which can restrict availability and create logistical challenges for patients. By leveraging telehealth, the company is able to extend its reach to a broader population while maintaining the safeguards associated with prescription-based care.
Looking ahead, this model could serve as a blueprint for future innovations in the delivery of advanced therapies, particularly in fields where convenience, personalization, and ongoing monitoring are critical. As healthcare continues to evolve toward more decentralized and technology-enabled systems, initiatives like this are likely to play an increasingly important role.
In summary, Niagen Bioscience’s launch of its clinician-directed telehealth platform and at-home injection kit represents a notable advancement in the accessibility of NAD+ therapies. By integrating medical oversight with modern delivery mechanisms, the company is aiming to provide a high-quality, patient-centered solution that aligns with the growing demand for innovative approaches to healthy aging.
About Niagen Bioscience:
Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription.
